GlassScriptPhysician profile
Ashley Nickole Schultz
NPI 1558879106
$12,119.03
in general payments reported to CMS, 2019-2025
34 companies · $1,346 in 2025
The $1,346 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,229 · 2022: $1,797 · 2023: $6,427 · 2024: $1,320 · 2025: $1,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,158 · Travel and Lodging: $3,881 · Education: $54.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,157.94 |
| Travel and Lodging | $3,881.12 |
| Education | $54.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,202.39 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Nalu Medical, INC. | $2,590.70 | 2023-2024 | Nalu Neurostimulation System |
| Boston Scientific Corporation | $1,322.09 | 2022-2025 | Intracept |
| Abbvie INC. | $782.80 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $648.85 | 2021-2025 | Xtampza, Belbuca, Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $411.73 | 2021-2025 | Relistor |
| Lundbeck LLC | $355.44 | 2024-2025 | Vyepti |
| Lilly USA, LLC | $272.56 | 2021-2024 | Emgality |
| Averitas Pharma INC. | $249.95 | 2023-2025 | Qutenza |
| Abbott Laboratories | $228.85 | 2021-2024 | Eterna |
| Nevro Corp. | $177.40 | 2021-2024 | Senza |
| Pfizer INC. | $157.76 | 2023-2025 | |
| Redhill Biopharma INC. | $93.75 | 2021 | |
| Allergan, INC. | $63.45 | 2021 | |
| Grt US Holding, INC. | $62.29 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Protega Pharmaceutials INC | $48.25 | 2025 | Roxybond |
| Vertos Medical, INC. | $43.17 | 2024 | Mild Device Kit |
| Biodelivery Sciences International, INC. | $41.91 | 2021 | |
| Hikma Pharmaceuticals USA | $40.37 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $39.11 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $25.56 | 2021 | |
| Almatica Pharma LLC | $24.44 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $23.85 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.29 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $22.06 | 2025 | Ajovy |
| Ucb, INC. | $20.65 | 2024 | Fintepla |
| Kowa Pharmaceuticals America, INC. | $20.07 | 2023 | Seglentis |
| Argenx US, INC. | $19.38 | 2024 | Vyvgart Hytrulo |
| Neurocrine Biosciences, INC. | $19.23 | 2024 | Ingrezza |
| Pacira Therapeutics, INC. | $18.93 | 2021 | |
| Spr Therapeutics, INC | $18.73 | 2023 | Sprint Pns System |
| Amgen INC. | $18.12 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $17.14 | 2025 | |
| Tonix Medicines, INC. | $14.76 | 2025 | Tonmya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.